Onco360 Added To Gazyva™ Limited Distribution Network

NEW YORK - Nov. 18, 2013 - PRLog -- The FDA recently approved Genentech’s new cancer therapy, Gazyva (obinutuzumab), for adult patients diagnosed with chronic lymphocytic leukemia (CLL).  Gazyva is an injection for intravenous infusion, and in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic CLL¹.

Onco360 has been chosen as one of the select pharmacies in the Gazyva limited distribution network, and has the product in stock and immediately available for prescription order.  Onco360 dispenses through its network of JACHO-accredited, OncoMed Pharmacies, outfitted with USP-795/797 compliant positive and negative pressure clean rooms.

“Gazyva is the eighth limited distribution product Genentech has entrusted Onco360 with.  I am extremely proud of our organization and the higher level of patient and physician support we consistently provide,” said Burt Zweigenhaft, CEO of Onco360, adding, “We are very pleased to be well regarded by leading Oncology Pharmaceutical Manufacturers, and we look forward to fostering our excellent working relationships with them by continuing to provide the highest level of Oncology Pharmacy care.”

For more information about Onco360 please visit Onco360.com (http://www.Onco360.com).

1. Gazyva Prescribing Information http://www.gene.com/download/pdf/gazyva_prescribing.pdf